Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: Vaccine-induced activation of antigen presenting dendritic cells

Journal of Hepatology

Volumn 30, Issue 5, 1999, Pages 755-764

  Akbar, Fazle ^a   Abe, Masanori ^a   Masumoto, Toshikazu ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cells; Hepatitis B surface antigen; Hepatitis B virus; Transgenic mice; Vaccine therapy

Indexed keywords

CD86 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0344603602     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80125-1     Document Type: Article

References (33)

1. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using costeffectiveness analysis. Ann Intern Med. 118:1993;298-306.
2. Peters M, Vierling J, Grenshwin ME, Millich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology. 13:1991;977-994.
3. Sherker A, Marion P. Hepadnavirus and hepatocellular carcinoma. Annu Rev Immunol. 45:1991;475-508.
4. Periollo RP. Treatment of chronic hepatitis B. Hollinger FB, Lemon S, Magolis HS, . Viral Hepatitis and Liver Disease. 1991;616-623 Williams & Wilkins, Baltimore.
5. Shaw T, Civitico GM, Newbold JE. New approaches for antiviral chemotherapy. Antiviral Chem Chemother. 7:1996;53-64.
6. Burke DS. Vaccine therapy for HIV, a historic view of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. Vaccine. 11:1993;883-891.
7. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with herpes simplex virus glycoproteins; protection against initial and recurrent genital herpes. J Infect Dis. 155:1987;914-920.
8. Stanford JL. The history and future of vaccination and immunotherapy for leprosy. Trop Geogr Med. 46:1994;93-107.
9. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother. 49:1995;105-109.
10. Pol S, Driss F, Michel M, Nalpes B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. [letter] Lancet. 344:1994;342-343.
11. Wen Y-M, Wu X-H, Hu D-C, Zhang Q-P, Guo S-Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. [letter] Lancet. 345:1995;1575-1576.
12. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest. 95:1995;341-349.
13. Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, Matsubara K, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA. 86:1989;207-211.
14. Akbar SMF, Kajino K, Tanimoto T, Kurose K, Masumoto T, Michitaka K, et al. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol. 26:1997;131-137.
15. Akbar SMF, Onji M, Inaba K, Yamamura K, Ohta Y. Low responsiveness of hepatitis B virus transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells. Immunology. 78:1993;468-475.
16. Akbar SMF, Inaba K, Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice: abrogation of immune response defect to a T-cell-dependent antigen. Immunology. 87:1996;519-527.
17. Metlay JP, Witmer-Pack MD, Agger P, Crowley MT, Lawless D, Steinman RM. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med. 171:1990;1753-1771.
18. Inaba K, Metlay JP, Crowley MT, Steinman RM. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med. 172:1990;631-640.
19. Crowley M, Inaba K, Witmar-Pack M, Steinman RM. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol. 118:1989;108-125.
20. Waters JA, Kennedy M, Voet P, Huaser P, Petre J, Carmen W, et al. Loss of the common"A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 90:1992;2543-2547.
21. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:1991;271-296.
22. Mactonia SE, Patterson S, Knight SC. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 67:1989;285-289.
23. Gabrilovich DI, Patterson S, Harvey JJ, Woods GM, Elsley W, Knight SC. Defects in the function of dendritic cells in murine retroviral infection. Adv Exp Med Biol. 378:1995;469-472.
24. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med. 173:1991;531-538.
25. Kurose K, Akbar SMF, Yamamoto K, Onji M. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology. 92:1997;494-500.
26. Matzinger P. Tolerance, danger and extended family. Annu Rev Immunol. 12:1994;991-1045.
27. Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science. 271:1996;1723-1726.
28. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and disease. Hepatology. 22:1995;1316-1325.
29. Schirmbeck R, Melber K, Kuhrober A, Janowicz ZA, Reimann J. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J Immunol. 152:1994;1110-1119.
30. Schirmbeck R, Melber K, Mertens T, Reimann J. Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monometric hepatitis B virus surface (S) antigen. Eur J Immunol. 24:1994;1010-1088.
31. Schirmbeck-R, Reimann-J. "Empty" Ld molecules capture peptides from endocytosed hepatitis B surface antigen particles for major histocompatibility complex class I-restricted presentation. Eur J Immunol. 26:1996;2812-2832.
32. Akbar SMF, Horiike N, Onji M. Prognostic importance of antigen presenting dendritic cells during vaccine therapy in hepatitis B virus transgenic mice. Immunology. 1998;. (in press).
33. Bergstresser PR, Kitajima T, Xu S, Arizumi K, Takashima A. T cell-mediated terminal maturation of dendritic cells. Adv Exp Med Biol. 417:1997;65-69.